Granules India has received regulatory approval from U.S. authorities for a medication used in the treatment of Attention Deficit Hyperactivity Disorder, marking a notable milestone in the company’s international growth strategy. The clearance enables the pharmaceutical manufacturer to expand its presence in the world’s largest drug market while reinforcing its reputation as a reliable supplier of complex generics. Industry analysts view the development as a positive signal for Granules India’s revenue visibility, given the steady demand for central nervous system therapies.